Previous 10 | Next 10 |
i31-GEP integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing pers...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced data from an independent, prospective study published in the American Journal of Surgery demonstrating Decisio...
Study published in JCO Precision Oncology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outco...
Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert”...
The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter post-COVID future for the company, Canaccord Genuity has upgraded the stock to buy from hold with the pri...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th...
Cross-Sectional Study of 589 U.S. Dermatological Clinicians Demonstrating Clinical Utility Was Recently Published in SKIN: The Journal of Cutaneous Medicine Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information ...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Castle Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation
Castle Biosciences, Inc (CSTL) Q4 2020 Earnings Conference Call March 8, 2021 4:30 PM ET Company Participants Derek Maetzold - Founder, President, and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Paul Knight - KeyBanc S...
Castle Biosciences(CSTL) announced that DecisionDx-Melanoma, the company's prognostic gene expression profile test for cutaneous melanoma, now utilizes an Integrated Test Result ((ITR)), designed to provide a more precise risk prediction in patients with stage I, II or III melanoma.DecisionDx...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...